Ranked among the top 1% of companies assessed in the pharmaceutical industry
Leading the way in Green CRDMO
Driving innovation for a healthier future
SHANGHAI, Feb. 10, 2025 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has been recognized as a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics. This marks the fifth consecutive year that the company has been among the highest scorers in ESG Risk Ratings. Sustainalytics, a prominent ESG data, research, and ratings firm, assists global investors in developing and implementing responsible investment strategies.
WuXi Biologics’ commitment to excellence and sustainability has placed it in the top 1% of companies assessed in the pharmaceutical industry. The company’s dedication to driving innovation for a healthier future has cemented its position as a leader in Green CRDMO. By focusing on creating long-term value for all stakeholders, WuXi Bio continues to set the standard for environmental, social, and governance practices in the industry.
With a strong track record of ESG performance, WuXi Biologics is not only meeting industry standards but exceeding them. The company’s recognition as a top-rated ESG company showcases its unwavering commitment to sustainability and responsible business practices. Investors and stakeholders can trust in WuXi Bio’s dedication to creating a positive impact on the world.
Impact on Individuals
WuXi Biologics’ continued success as a top-rated ESG company can have a positive impact on individuals, including employees, investors, and consumers. Employees can take pride in working for a company that prioritizes sustainability and ethical practices. Investors can feel confident in supporting a company with a strong ESG track record, knowing that their investments align with their values. Consumers can trust in the products and services offered by WuXi Bio, knowing that they are made with a commitment to environmental and social responsibility.
Global Impact
WuXi Biologics’ leadership in ESG practices has a significant global impact, setting a standard for other companies to follow. By driving innovation for a healthier future and creating long-term value for all stakeholders, WuXi Bio is contributing to a more sustainable and ethical global pharmaceutical industry. As a top-rated ESG company, WuXi Biologics is inspiring positive change and promoting responsible business practices worldwide.
Conclusion
WuXi Biologics’ recognition as a top-rated ESG company by Morningstar Sustainalytics is a testament to the company’s commitment to excellence, innovation, and sustainability. By leading the way in Green CRDMO and driving positive change in the pharmaceutical industry, WuXi Bio is setting a new standard for environmental, social, and governance practices. As individuals and the world as a whole, we can all benefit from the positive impact of WuXi Biologics’ dedication to creating a healthier, more sustainable future for everyone.
